Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Comcast Corporation (CMCSA) vs Illumina, Inc. (ILMN) Price & Performance

Comcast CorporationTrade
Illumina, Inc.Trade

Price performance (Past 24H)

Key statistics

Comcast Corporation vs Illumina, Inc. — how do they compare? Comcast Corporation trades at $23.28 (market cap $82.84B), while Illumina, Inc. trades at $191.2 (market cap $28.93B). The key difference: Comcast Corporation is far larger — about 2.9× Illumina, Inc.'s market cap, and Comcast Corporation pays a 5.69% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.

CMCSAILMN
Market Cap
$82.84B$28.93B
Sector
MediaHealth
52-Week High
$33.81$194.33
52-Week Low
$22.32$91.00
Enterprise Value
$167.98B$30.32B
Dividend Yield
5.69%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Comcast Corporation

Comcast (CMCSA) trades at $23.97, up 1.7% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with a 16.16% net margin and attractive valuation metrics including P/E of 4.7 and P/B of 0.97. Recent quarterly earnings consistently beat expectations, while strategic moves include the NBCUniversal spin-off and Sky's acquisition of ITV's media unit for $2.14 billion.

The stock presents compelling value with significant upside to the $29.94 consensus target. However, investors face risks from Starlink competition and integration challenges from recent acquisitions. Wall Street maintains strong buy sentiment with 58% analyst support, but execution risks and sector disruption threats warrant careful monitoring.

Illumina, Inc.

Illumina (ILMN) trades at $190.05, showing strong momentum with a 43.7% gain year-to-date and recent earnings beats. The stock is technically bullish, trading near resistance at $191 with solid fundamentals including 19.42% net margins and robust cash flow. Recent leadership appointments and product launches like StrataMap Spatial Solution highlight ongoing innovation in genomics sequencing.

Outlook remains positive driven by sequencing demand and margin expansion, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is bullish with 51% buy ratings, though the current price exceeds the $174.44 target, suggesting near-term valuation concerns.

Returns comparison

Trailing returns across standard periods

About Comcast Corporation

Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.

Read more on CMCSA

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Read more on ILMN